Shares of Stemline Therapeutics Inc. (NASDAQ:STML) were up 4.4% during trading on Monday . The stock traded as high as $7.90 and last traded at $7.80, with a volume of 192,309 shares. The stock had previously closed at $7.47.

Several analysts have commented on STML shares. Jefferies Group restated a “buy” rating on shares of Stemline Therapeutics in a report on Friday, August 5th. Roth Capital restated a “buy” rating and set a $32.00 target price on shares of Stemline Therapeutics in a report on Thursday, June 9th. Wedbush restated an “outperform” rating and set a $16.00 target price on shares of Stemline Therapeutics in a report on Tuesday, June 7th. Finally, Zacks Investment Research downgraded shares of Stemline Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, July 12th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $19.56.

The firm has a 50-day moving average of $7.14 and a 200 day moving average of $5.95. The firm’s market capitalization is $126.45 million.

Stemline Therapeutics (NASDAQ:STML) last issued its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.03. Equities analysts predict that Stemline Therapeutics Inc. will post ($2.14) earnings per share for the current fiscal year.

A hedge fund recently raised its stake in Stemline Therapeutics stock. Royce & Associates LLC raised its stake in shares of Stemline Therapeutics Inc. (NASDAQ:STML) by 318.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 159,179 shares of the biopharmaceutical company’s stock after buying an additional 121,179 shares during the period. Royce & Associates LLC owned approximately 0.91% of Stemline Therapeutics worth $1,004,000 as of its most recent filing with the SEC.

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.